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focused around more scrutiny in the reimbursement assessment of orphan 
drugs. ConClusions: All twenty stakeholders gave recommendations about a 
stronger European cooperation for the value assessment of orphan drugs, with 
eleven stakeholders suggesting a European reimbursement system for orphan 
drugs.
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ConSideration For rare diSeaSeS in drug reimburSement deCiSion-
making
Gosain S1, Coyle D1, Clifford T2, Jones B3
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objeCtives: Reimbursement processes have been implemented to inform which 
therapies should be funded in light of scarce health care resources. However, the 
applicability of standard processes to drugs for rare diseases is heavily debated. As 
a result of the small patient populations affected by rare diseases, coupled with a 
limited understanding of the natural history of these conditions and the high cost of 
these treatments, it is argued that drugs for rare diseases may not meet the eviden-
tiary standards routinely applied when making resource allocation decisions. This 
study identified current reimbursement processes for prescription pharmaceuticals 
both within Canada and internationally, with the objective of assessing how drugs 
for rare diseases are considered within existing processes. Methods: Using the 
G20 countries as a sampling frame, a review of published and grey literature was 
conducted to identify the reimbursement processes used in 28 countries, and in 
Canadian provinces/territories. A search for peer-reviewed publications was con-
ducted using Medline, Scopus, CINHAL, EconLit and PsychInfo. The grey literature 
search included websites of health technology assessment agencies and govern-
ment agencies. Results: Drugs for rare diseases are considering uniquely for reim-
bursement within three Canadian provinces and seven countries. Reimbursement 
frameworks focused specifically on the reimbursement of drugs for rare diseases 
are limited. In some jurisdictions, drugs for rare diseases are considered uniquely 
within the established decision-making process for drugs. Varying decision criteria 
are applied within the identified processes for the reimbursement of drugs for rare 
diseases. ConClusions: This review identifies approaches for making resource 
allocation decisions for drugs; explicitly considering funding decisions related to 
drugs for rare diseases. An understanding of these frameworks and the decision 
criteria applied when making resource allocation decisions may help inform the 
development of more standardized approaches for the reimbursement of drugs 
for rare diseases.
PSY74
the eConomiC and humaniStiC burden oF relaPSed/reFraCtorY (r/r) 
indolent non-indolent non-hodgkin’S lYmPhoma (inhl): an evidenCe 
gaP analYSiS
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objeCtives: To identify research studies that examine the economic and/or 
humanistic burden of R/R iNHL, and identify evidentiary gaps which could be 
informed by future research. Methods: iNHL refers to a group of largely incur-
able slow-growing lymphomas that run a relapsing course after therapy, and 
can lead ultimately to life-threatening complications. Although many thera-
pies are available, patients eventually relapse and become refractory to existing 
therapies. As such, additional treatment options with improved response rate, 
durability of response and more manageable toxicity are needed to treat patients 
with R/R iNHL. A structured literature search was performed to assess the eco-
nomic and patient burden of iNHL. English-language articles published since 
2009 were systematically reviewed in PubMed, EMBASE and Cochrane databases. 
Additionally, searches from global HTA organizations and conference abstracts 
were performed. Research was considered relevant to the economic and human-
istic burden of iNHL based on reported outcomes such as resource utilization, 
costs, or relevant patient-reported outcomes associated with relapsed/refractory 
iNHL. Results: Few cost-of-illness studies or HTAs address iNHL. Evidence was 
limited to hospital-based direct treatment costs, omitting societal and indirect 
costs of the disease. Multiple cost-effectiveness analyses were identified focusing 
on Rituximab; however, few studies evaluated the cost-effectiveness of alterna-
tive 2nd or 3rdline therapies in the case of R/R iNHL. The majority of identified 
patient reported outcomes (PRO) research exists as conference abstracts. No stud-
ies were identified that examine PRO in a R/R iNHL population. ConClusions: 
The economic and humanistic burden of R/R iNHL has not been widely reported 
in the literature. Areas of future research may include evaluating both direct 
and indirect costs in R/R iNHL. PROs are not well understood in iNHL, and future 
research should focus on QoL and related factors that may help evaluate any 
trade-off between progression-free survival and the severity/duration of adverse 
events.
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objeCtives: In context of Health Technology Assessment (HTA) decision frame-
work, some countries (e.g. Germany) have a special regulation for orphan drugs 
(OD), while others (e.g. France) don’t. The aim of the study was to compare the 
HTA decisions, prices and reimbursements for the OD that have been evaluated in 
France and Germany. Methods: We selected OD assessed under AMNOG law in 
Germany and reviewed HTA assessments from the Transparency Committee (TC) 
for France and from IGWiG/G-BA for Germany, and extracted prices and reimburse-
These analyses suggest that OXY access restrictions such as PA and TC did not 
result in cost savings.
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eStimated error in uSing national inCidenCe FigureS verSuS State 
eStimateS For rare diSeaSe CalCulationS oF eStimated CaSeS and 
CoSt Per CaSe deteCted in newborn SCreening (nbS)Congenital 
adrenal hYPerPlaSia (Cah) and Congenital hYPothYroidiSm (Ch)
Alotaibi A, Rittenhouse B
MCPHS University, Boston, MA, USA
objeCtives: In 2006, the American College of Medical Genetics (ACMG) recom-
mended a significantly expanded group of rare conditions for state-based US 
NBS programs. Initial efforts to explore the implications of this expansion used 
national incidence data applied to the states due to an inability to gather current 
state-specific numbers. Older state-specific numbers were later identified. This 
research assesses the error associated with estimating consequences of these 
programs by using national vs. state-specific incidence estimates. Methods: We 
collected data on national disease incidence and state-specific numbers of births 
(2011), state-specific disease cases (2003 and 2006) and number of required NBS 
tests/birth and reported fees. We developed two estimates of cases: 1) expected 
cases by applying national incidence to current state births and 2) cases identified 
using state-specific actual observations (averaged over the 2 years and applied 
to current number of births). We also calculated the cost per expected identified 
case using both methods of estimating cases. Results: The differences in num-
bers based on state actuals vs. expected cases calculated from national incidence 
estimates was expressed as a percentage of the actuals. For CH this ranged from 
-71% to + 200% (mean= -33%; 46 were negative; 2 were positive; 3 unchanged) and 
in CAH from -67% to + 500% (mean= +70%; 9 were negative; 22 were positive; 7 
unchanged and 13 missing or undefined due to no cases being in the denominator 
of the calculation). Similar differences were observed in calculations of cost per 
identified cases. ConClusions: Sampling variation and the association with 
ethnicity and other differences by state demographics implied added variation 
in state actuals compared to national incidence used in predictions. The one-
sided error observed in the CH calculations leads us to question the accuracy of 
the national incidence figure. Application of national incidence to state-specific 
situations should proceed with caution.
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inter-temPoral Change oF bodY maSS index in brazilwhat iS the role 
oF Food PriCeS?
Balbinotto G, Cardoso L
Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil
bACkgRound:: Obesity can be understood as a problem resulting from the imbal-
ance between the intake and the individual caloric expenditure, which has sparked 
concern among researchers and policymakers in public health. The alert comes 
up with the fast growth in the prevalence of obesity in adults and children in 
Brazil. objeCtives: In this context, the challenge of this essay is to analyze the 
major changes in BMI between 2002 and 2009 and to estimate the relationship 
between food prices and obesity, in order to check the effect of food prices on BMI 
in Brazil. Methods: To assess the changes in BMI over time, first of all, we analyze 
its distribution using the relative distribution method proposed by Handcock and 
Morris (1998). Then, recentered influence function (RIF) regressions were applied 
to decompose the changes in the BMI distribution into composition and struc-
ture effects and identify the specific contribution of food prices. The empirical 
estimates needed are based on micro-data from household budget survey in 
two points of time: 2002-2003 and 2008-2009 accomplished by the Brazilian 
Institute of geography (IBGE). Were considered only the information regarding 
the adult population aged less than 20 years. Results: The main changes in 
BMI distribution showed that the density has moved to the right over the time 
and there were increases in the right hand tail. Despite the small effect, the RIF 
results show that the prices variations over the period contributed to change BMI. 
If prices had not changed, the median BMI would be 0.22 higher. The increases in 
the prices of meat, ssb and fruits and vegetables showed the greatest mean effects 
on BMI, especially to upper quantiles of the distribution. There are also evidences 
that income and age contributed to rise BMI, while education is associated to a 
lowering effect.
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Stakeholder analYSiS
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objeCtives: In 2000 the Orphan Drug Act was designed to supported drug devel-
opment for rare disease in Europe. Now thirteen years after the Act was passed, 
orphan drug development has immensely increased and health care systems 
are challenged to find more appropriate assessment mechanism for the reim-
bursement of orphan drugs. Public awareness has lately been raised by major 
discussions about the discontinuation of reimbursement for several orphan drugs. 
By conducting qualitative interviews this article aims to identify the view of dif-
ferent stakeholders about recent and future changes within the reimbursement 
assessment and its evidence requirements for orphan drugs. Methods: Twenty 
semi-structured interviews were conducted with relevant stakeholders from the 
orphan drug community. Interviewees were scientific experts, reimbursement 
agencies, industry and patient organizations from five European countries. The 
interviews were analyzed with the framework analysis technique. Results: 
All twenty stakeholders have reported about recent or future changes in their 
national reimbursement practice for orphan drugs. The most emerging theme 
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primary target for drug-seeking patients, this pilot study was conducted to validate 
a survey instrument designed to assess emergency physicians (EPs) intention to 
use the recently available Texas PMP. Methods: A cross-sectional survey of EPs 
was conducted at a statewide emergency medicine conference. A 34-item ques-
tionnaire, based on the Technology Acceptance Model (TAM), was developed to 
assess EPs intention to use the Texas PMP. Items related to technology acceptance 
(perceived ease of use, perceived usefulness, attitude, and intention) were assessed 
using 5-point Likert scale responses (1= strongly disagree to 5= strongly agree). The 
survey expanded on a previous exploratory survey of EPs. Correlation analyses 
were used to validate the survey instrument scales. Results: Of the 45 respond-
ents, most were male (68.9%), attending EPs (57.8%), with 10.8±11.1 years in emer-
gency medicine, from a community hospital setting (55.6%), and were users of the 
Texas PMP (51.2%). Among those who were not registered, 39.2% reported lack of 
awareness as the primary reason for not being registered. Standardized Cronbach’s 
alphas for the constructs of perceived ease of use, perceived usefulness, attitude, 
and intention for PMP users were 0.88, 0.90, 0.74, and 0.84, respectively; and 0.77, 
0.87, 0.84, and 0.74, respectively for PMP non-users. ConClusions: Considering 
the ED as a source of diversion, it is important to understand EPs utilization of 
PMPs. EPs use of PMPs may help to mitigate the economic burden associated with 
the non-medical use of prescription opioids, while improving patient outcomes. 
Future studies using this survey instrument are needed to further assess the 
predictive utility.
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an evaluation oF oPioid overutilization QualitY metriCS uSing 
reCeiver oPerating CharaCteriStiC CurveS and ProxieS For 
overutilization
Durkin M1, Lopatto J1, Mody SH1, Pesa JA1, Marcus SC2
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2School of Social Policy and Practice, University 
of Pennsylvania, Philadelphia, PA, USA
objeCtives: To evaluate the sensitivity and specificity of opioid overutilization 
quality measures based on the Centers for Medicare and Medicaid Services (CMS) 
Controlled Substance Overutilization Monitoring System (OMS) using proxy indica-
tors of potential overutilization. Methods: Based on the CMS measure (propor-
tion of patients with opioid prescriptions from ≥ 4 prescribers and ≥ 4 pharmacies 
among patients with ≥ 2 opioid prescriptions), claims from the 2012 IMS LRx data-
base were used to evaluate the metric at different prescriber and pharmacy thresh-
olds. Cash payment of ≥ 1 opioid prescription was used as a proxy for potential 
overutilization and set as the dependent variable in logistic regression models to 
generate separate receiver operating characteristic (ROC) curves for thresholds 
of 2-8 prescribers and 2-8 pharmacies. Optimal cutpoints for number of physi-
cians and pharmacies were selected as the value on the curve with the shortest 
distance to perfect prediction. Sensitivity, specificity and positive predictive value 
(PPV) for every combination were calculated. As a sensitivity analysis, the process 
was repeated using ≥ 1 opioid-abuse related diagnosis as a proxy for potential 
overutilization. Results: Of the 1,213,909 qualified patients, 5.9% met the CMS 
criteria for overutilization, while 13.8% met the alternative ROC optimal criteria 
(≥ 4 prescribers and ≥ 3 pharmacies). Defining cash payment patients (12.3% of 
total) as overutilizers, the CMS definition had sensitivity (15.0%), specificity (95.3%) 
and PPV (31.0%) The ROC alternative had sensitivity (28.0%), specificity (88.2%) and 
PPV (24.9%). For patients with opioid abuse-related claims defined as overutiliz-
ers (2.6% of total), the CMS criteria had sensitivity (16.1%), specificity (94.3%) and 
PPV (7.0%). The ROC alternative had sensitivity (28.5%), specificity (86.6%) and 
PPV (5.3%). ConClusions: Using two proxies for opioid overutilization, analy-
sis of ROC curves suggested optimal criteria similar to the CMS criteria. Quality 
organizations can use the range of results and their preferences for sensitivity 
and specificity tradeoffs to develop needed quality measures.
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the imPortanCe oF FaCt over oPinion in ChoiCe oF ConditionS to be 
reCommended For newborn SCreening (nbS)
Rittenhouse B
MCPHS University, Boston, MA, USA
objeCtives: In 2006, the American College of Medical Genetics (ACMG) recom-
mended expanding NBS. Recommendations relied largely on a stakeholder survey 
on 19 attributes of different rare conditions under consideration. The percentage of 
respondents agreeing to an attribute’s presence determined its score. This research 
examines one particular attribute and asks how the recommendation of included 
conditions changes with the substitution of scoring based on the actual facts for that 
based on surveyed opinion. Methods: The original report indicated each condi-
tion’s scores for survey questions. Unlike some questions, that of whether multiplex 
technologies (allowing multiple conditions to be screened with a single test) were 
available, had a correct answer. Original scores for the question totaled between 
0-200, depending on the respondents’ percentage indicating yes. Answers were 
re-scored 200 or 0 as factually appropriate - existence/non-existence of multiplex 
screening for each condition. Results: After eliminating conditions with missing 
data, 78 out of the original 84 conditions remained. 42 conditions (54%) increased 
their scores; 30 (38%) decreased. Of conditions with increasing scores, the mean 
increase was 85. Of conditions decreasing their scores, the mean decrease was 43. 
We estimate the potential change in recommendations as 4 conditions moving from 
the Core to secondary or Not Recommended and 10 moving from Secondary to Core 
status. ConClusions: As the only conditions capable of having recommendations 
altered by this correction were those roughly 200 points +/- category cutoffs and 
some ACMG rules further limited reclassification, this single correction was limited 
in its ability to alter recommendations (67% of the conditions could not change). 
Nonetheless the changes were significant (of those that could change, 50% did). As 
other questions in the survey were also questions of fact, doing a similar analysis 
for all such questions could further significantly alter the conditions recommended 
for the panel.
ment levels of these drugs in both countries. Results: Eight OD were identified. 
In Germany, G-BA decisions related to additional benefit were non-quantifiable for 
3 drugs, minor for 4 drugs, and minor in one subgroup and considerable in other 
subgroup for one drug. In France, one product was not assessed by the TC, and 
improvement in actual benefit (IAB) was rated as weak for 4 products, moderate for 
2 products and important for one product. In Germany all these drugs were 100% 
reimbursed, while in France, depending on actual benefit (AB) ratings, reimburse-
ment levels varied from non-reimbursement to 100%. At time of analysis, reim-
bursement status was granted in France for only 4 products (15% for one drug, 65% 
for one drug and 100% for 2 drugs). In Germany, OD prices were about 20% higher 
than in France before rebates, and about 20% lower after rebates. ConClusions: 
Substantial improvement for OD were less frequently acknowledged by German 
HTA than by French HTA and prices appeared to be lower in Germany than in 
France. However, price volume agreements in France might have contributed to 
hidden discounts. Access level of OD appeared higher in Germany.
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health eConomiCS and outComeS data reQuirementS in indolent 
non hodgkinS lYmPhoma (inhl) and ChroniC lYmPhoCYtiC leukemia 
(Cll) From united StateS PaYer PerSPeCtive
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objeCtives: To understand current considerations and management of the iNHL 
and CLL disease states and the extent to which health economic outcomes data 
informs payer decision making process. Methods: A national level in-depth tel-
ephone survey of 45 payers was done in the month of November, 2013. The payer 
mix included both Commercial (n= 20) and Medicare (n= 25) payers that were either 
medical or pharmacy directors to determine clinical, economic and humanistic 
outcomes data critical for formulary and medical policy deicisons for iNHL and 
CLL. Results: US Payers are most interested in the endpoints that directly tie to 
their major cost drivers: hospitalization, re-hospitalization and emergency ser-
vices in both the disease state. Payers were split on preferring the comparative 
data of the cost-effectiveness analysis and the simple presentation of a budget 
impact model. There was no difference in payer types when it came to preference 
for any particular health economics model. Amongst the various adverse events 
related to treating iNHL and CLL, neutropenia is the most concerning adverse 
event from payer perspective, given the associated high cost of related treatments 
and hospitalizations. Payers consistently reported that the greatest unmet need 
in the iNHL and CLL today is more treatment options for relapsed and refractory 
patients, with greater response rates, increased durability of response and less 
toxicity leading to increased overall survival and progression. ConClusions: 
While in iNHL/CLL space payers admit decisions are based more on clinical evalu-
ations rather than cost drivers, payers appreciate the value of demonstrating a 
reduction in resource utilization costs as they can directly evaluate the impact of 
this data on their health plan.
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PatientS with relaPSed or reFraCtorY ChroniC lYmPhoCYtiC 
leukaemia (r/r Cll) ineligible For CYtotoxiC theraPYwho are theY 
and what iS their unmet need?
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objeCtives: To identify criteria used to categorize patients with R/R CLL who are 
ineligible for cytotoxic therapy and the unmet need in these patients. Methods: 
Structured searches related to R/R CLL; performance status; comorbidities; organ 
function; and treatment patterns were performed on PubMed, Google Scholar, 
and the Cochrane databases and supplemented with hand searches of published 
literature, clinical guidelines, and online sources. Results: 440 publications were 
identified. 123 were considered relevant to the study. Patients ineligible for cyto-
toxic therapy were identified by a combination of assessments for performance 
status (using ECOG), comorbidities (CIRS), and organ function (creatinine clear-
ance (CrCl)). Unfit patients are “> 65 years with a comorbidity” (ECOG 3–4 or CIRS 
> 6 or CrCl < 70 mL/min). NCCN clinical guidelines do not refer to assessment 
scores or define unfit: the NCCN categorizes R/R CLL patients as “≥ 70 years, or 
younger with comorbidities” or “frail with significant comorbidity”. These criteria 
are not aligned with others such as slow-go (ECOG 2–4 or CIRS > 6 or CrCl < 70 mL/
min) and no-go (fatal comorbidities with very short life-expectancy). Treatment 
regimens recommended by the NCCN contain drugs contraindicated for common 
comorbidities. The RCTs for the recommended regimens did not include patients 
with contraindicated comorbidities. There is an unmet need in these patients 
for appropriate treatment. ConClusions: There exists unmet need in patients 
identified as unfit using current criteria: they can be restricted from recommended 
drugs due to contraindications for common comorbidities. Most of these patients 
also have not been included in RCTs. Criteria used to identify patients with R/R CLL 
ineligible for cytotoxic therapy are not yet standardized; standardized assessments 
are needed for uniform identification and RCT enrolment.
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emergenCY PhYSiCianS’ intention to uSe the texaS PreSCriPtion 
monitoring Programa Pilot StudY
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objeCtives: Inappropriate use of prescription opioids costs insurers over $72 
billion annually in direct health care expenses. Prescription monitoring programs 
(PMP) are state-operated databases which allow authorized clinicians (e.g., pre-
scribers, pharmacists) to query a patient’s opioid dispensing history via a secured 
online connection, during patient care. Since the emergency department (ED) is a 
